Stockreport

Moleculin Hits 45 Subject Enrollment Milestone, Triggering Final Countdown to Mid-2026 MIRACLE Trial Data Readout [Yahoo! Finance]

Moleculin Biotech, Inc.  (MBRX) 
Last moleculin biotech, inc. earnings: 8/16 05:35 pm Check Earnings Report
US:NASDAQ Investor Relations: moleculin.com/investors
PDF Early Blinded Results Show 40% Remission Rate Across Difficult-to-Treat Patient Population Enrollment Accelerating Toward 90 Subject Threshold as Phase 3 Pathway Take [Read more]